Sotatercept improves hemodynamics, right heart function, and reduces the risk of adverse clinical outcomes in PAH patients not achieving low risk on background therapy
In recent randomized trials, add-on therapy with sotatercept led to improvements in hemodynamics and right heart function, and reduced the risk of adverse clinical outcomes in patients with pulmonary arterial hypertension who were not achieving low risk on maximal background therapy. This represents the first antiremodeling therapy approved for PAH, targeting dysregulation of the activin arm of the TGF-β pathway.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Sotatercept improves hemodynamics, right heart function, and reduces the risk of adverse clinical outcomes in PAH patients not achieving low risk on background therapy The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).
The Claim
Sotatercept improves hemodynamics, right heart function, and reduces the risk of adverse clinical outcomes in PAH patients not achieving low risk on background therapy
This conclusion is most relevant to: Patients with pulmonary arterial hypertension not achieving low risk on maximal background therapy.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives. (Circulation, 2026) —
How It Works
The proposed biological pathway:
- ▸Dysregulation of the activin arm of the TGF-β pathway drives vascular remodeling in PAH
- ▸Sotatercept targets this activin/TGF-β pathway dysregulation
- ▸Sotatercept inhibits aberrant signaling to reverse fibroproliferative vascular remodeling
- ▸Improved hemodynamics, right heart function, and reduced adverse clinical outcomes
Who Might Benefit
Evidence fit by population:
- ▸Patients with pulmonary arterial hypertension not achieving low risk on maximal background therapy
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Abstract does not provide specific effect sizes, sample sizes, or exact trial durations
- ▸Long-term safety and efficacy beyond the trial periods are not addressed in this abstract
- ▸Generalizability to PAH subtypes (e.g., methamphetamine-associated, schistosomiasis-associated) is unclear
Frequently Asked Questions
What is sotatercept and how does it work in PAH?▼
Sotatercept is the first antiremodeling therapy approved for PAH. It targets dysregulation of the activin arm of the TGF-β pathway, which is a critical driver of vascular remodeling in the disease.
Who is eligible for sotatercept treatment?▼
Sotatercept is indicated as add-on therapy for patients with PAH who are not achieving low risk despite maximal background therapy, including combination oral medications or parenteral prostacyclin.
What outcomes did sotatercept improve in clinical trials?▼
Recent randomized trials showed that sotatercept improved hemodynamics, right heart function, and reduced the risk of adverse clinical outcomes in PAH patients.
Is sotatercept a cure for PAH?▼
No, sotatercept is an add-on therapy that improves outcomes but does not cure PAH. Lung transplantation remains an important option for patients who remain at higher risk despite maximal therapy.
References
- 1.Humbert M, Zeder K, Kovacs G, Weatherald J. “Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives..” Circulation, 2026. PMID: 42441757 DOI: 10.1161/CIRCULATIONAHA.126.079274